



Universiteit
Leiden
The Netherlands

Challenging cases in high-risk prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy

Tappero, S.; Dell'Oglio, P.; Longoni, M.; Buratto, C.; Palagonia, E.; Scilipoti, P.; ... ; Galfano, A.

Citation

Tappero, S., Dell'Oglio, P., Longoni, M., Buratto, C., Palagonia, E., Scilipoti, P., ... Galfano, A. (2022). Challenging cases in high-risk prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy. *World Journal Of Urology*, 40(8), 1993-1999. doi:10.1007/s00345-022-04073-5

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3567620>

Note: To cite this publication please use the final published version (if applicable).



Challenging cases in high-risk prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy

Stefano Tappero^{1,4,5} · Paolo Dell'Oglio^{1,2,3} · Mattia Longoni¹ · Carlo Buratto¹ · Erika Palagonia^{1,6} · Pietro Scilipoti¹ · Enrico Vecchio^{1,4,5} · Marco Martiriggiano^{1,4,5} · Silvia Secco¹ · Alberto Olivero¹ · Michele Barbieri¹ · Giancarlo Napoli¹ · Elena Strada¹ · Giovanni Petralia¹ · Dario Di Trapani¹ · Aldo Massimo Bocciardi¹ · Antonio Galfano¹

Received: 30 March 2022 / Accepted: 7 June 2022 / Published online: 30 June 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract

Objective To evaluate the relationship between enlarged prostate, bulky median lobe (BML) or prior benign prostatic hyperplasia (BPH) surgery and perioperative functional, and oncological outcomes in high-risk (HR) prostate cancer (PCa) patients treated with Retzius-sparing robot-assisted radical prostatectomy (RS-RARP).

Methods 320 HR-PCa patients treated with RS-RARP between 2011 and 2020 at a single high-volume center. The relationship between prostate volume, BML, prior BPH surgery and perioperative outcomes, Clavien–Dindo (CD) grade ≥ 2 90-day postoperative complications, positive surgical margins (PSMs), and urinary continence (UC) recovery was evaluated respectively in multivariable linear, logistic and Cox regression models. Complications were collected according to the standardized methodology proposed by EAU guidelines. UC recovery was defined as the use of zero or one safety pad.

Results Overall, 5.9% and 5.6% had respectively a BML or prior BPH surgery. Median PV was 45 g (range: 14–300). The rate of focal and non-focal PSMs was 8.4% and 17.8%. 53% and 10.9% patients had immediate UC recovery and CD ≥ 2 . The 1- and 2-yr UC recovery was 84 and 85%. PV ($p=0.03$) and prior BPH surgery ($p=0.02$) was associated with longer operative time. BML was independent predictor of time to bladder catheter removal ($p=0.001$). PV was independent predictor of PSMs (OR: 1.02; $p=0.009$). Prior BPH surgery was associated with lower UC recovery (HR: 0.5; $p=0.03$).

Conclusion HR-PCa patients with enlarged prostate have higher risk of PSMs, while patients with prior BPH surgery have suboptimal UC recovery. These findings should help physicians for accurate preoperative counseling and to improve surgical planning in case of HR-PCa patients with challenging features.

Keywords High-risk prostate cancer · Robot-assisted radical prostatectomy · Retzius-sparing · Challenging scenarios · Functional outcomes

Stefano Tappero and Paolo Dell'Oglio: These authors equally contributed to the manuscript idealization and realization, and they should be considered as first and co-first author.

✉ Stefano Tappero
stefano.m.tappero@gmail.com

¹ Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

² Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands

³ Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

Introduction

Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) represents a valid surgical treatment option for prostate cancer (PCa) patients [1]. It allows the maximal

⁴ Department of Urology, IRCCS Ospedale Policlinico San Martino, University of Genova, Genova, Italy

⁵ Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy

⁶ Division of Urology, School of Medicine, Department of Clinical, Special and Dental Sciences, University Hospital “Ospedali Riuniti”, Marche Polytechnic University, Ancona, Italy

preservation of the structures of the Retzius space advocated to play a pivotal role in the continence mechanism [2], with consequent excellent functional outcomes in low- and intermediate-risk PCa patients. This advantage does not come at a significant oncological cost in expert hands [3–5]. Recent evidence suggested that RS-RARP is also feasible and safe in the specific setting of high-risk PCa patients [6] and in several atypical scenarios, such as enlarged prostate, bulky median lobe (BML), and previous benign prostate hyperplasia (BPH) surgery [7–9] with optimal oncological and functional outcomes. In these scenarios, the posterior approach may be more technically challenging, with consequent higher risk of postoperative complications and suboptimal perioperative oncological and functional outcomes [1, 10]. However, this has never been evaluated in the specific setting of high-risk PCa patients treated with RS-RARP. Under this light, relying on a large series of high-risk PCa patients treated at a single high-volume center, we hypothesized that patients presenting with one of the aforementioned challenging features have worse perioperative, oncological, and functional outcomes.

Materials and methods

Population

All consecutive patients with diagnosis of D'Amico high-risk PCa (clinical stage \geq T2c, biopsy Gleason score 8–10, or PSA levels > 20 ng/mL) [11] submitted to RS-RARP and pelvic lymph node dissection (PLND) at a single high-volume European institution (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) between January 2011 and December 2020 were recruited ($n = 340$). All RS-RARP procedures were performed with a four-arm da Vinci Si Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) with a trans-peritoneal approach, as previously described [6], by five experienced robotic surgeons. Patients' data were extracted from a retrospective database and only patients with complete pre-, peri- and postoperative data were included. Overall, 320 assessable patients were identified. The study protocol received the approval by the institutional medical ethics committee and all patients provided informed consent.

Evaluated variables and study endpoints

All patients underwent preoperative multi-parametric MRI or trans-rectal ultrasound of the prostate (TRUS). The distance between the bladder neck and the highest portion of the median prostatic lobe was assessed in MRI T2-weighted mid-sagittal images and TRUS mid-sagittal images. The bladder neck was defined as the proximal opening of the

prostatic urethra. BML was defined as a distance ≥ 10 mm between the bladder neck and the highest portion of the median prostatic lobe [8, 12].

History of previous BPH surgery was investigated during preoperative assessment and defined as previous transurethral resection of the prostate (TURP) or holmium/thulium laser enucleation of the prostate or simple open/minimally invasive prostatectomy. Prostate volume (PV) was defined as prostate weight at final pathology and considered as a continuous variable.

The endpoint of this study was to evaluate the relationship between PV, BML, prior BPH surgery and perioperative, oncological, and functional outcomes, in the specific setting of high-risk PCa patients. Specifically, we focused on:

- (a) Perioperative outcomes as surgical operative time, intraoperative blood loss, length of hospitalization and time to bladder catheter removal. A suprapubic tube is inserted under direct vision when the vesico-urethral anastomosis is completed. In case of bladder cancer history or very wide bladder neck the transurethral catheter is maintained and the suprapubic tube is not placed.
- (b) Oncological outcomes as positive surgical margins (PSMs). Focal and extended PSMs were defined as the presence of inked cells at the edge of the surgical specimen, for ≤ 1 mm and > 1 mm in length, respectively [1];
- (c) 90-day complications. Postoperative complications were collected based on patient chart review done by a dedicated data manager and were graded according to Clavien–Dindo classification system [13]. From July 2020 to January 2021 four medical doctors who were not involved in the treatment, performed patients' interviews to retrospectively collect 90-day postoperative complications. Postoperative complications were graded according to Clavien–Dindo classification system [13] and reported according to the standardized methodology proposed by the European Association of Urology ad hoc Complications Guidelines Panel in 2012 (Supplementary table 1a) [14–18];
- (d) Functional outcomes as urinary continence (UC) recovery. Immediate UC recovery was defined as the use of zero or one safety pad per day at catheter removal. UC recovery was defined as the use of zero or one safety pad per day at last follow-up. Continence recovery was assessed at each follow-up visit, namely at 3, 6, and 12 mo after surgery, then every 6 mo for 3 yr, and then annually.

Statistical analysis

Median and interquartile ranges (IQR) as well as frequencies and proportions were reported for continuous and

categorical variables, respectively. Seven separate sets of multivariable linear, logistic and Cox regression models were fitted to assess the relationship between challenging scenarios (i.e., PV, BML, prior BPH surgery) and operative time, intraoperative blood loss, length of hospitalization, time to bladder catheter removal, PSMs, at least one post-operative CD ≥ 2 and UC recovery. Adjustment variables were selected a priori. In multivariable models testing for perioperative outcomes, adjustment variables consisted of BMI, ISUP grade group at biopsy (1–3 vs 4–5), clinical T stage ($\leq T2$ vs. $\geq T3$), previous abdominal surgery and surgical experience (SE). SE was coded as the number of prior RS-RARP performed by each surgeon at the time of the index patient's operation, as previously done [19, 20]. In multivariable models predicting PSMs, adjustment variables consisted of ISUP grade group at biopsy, clinical T stage, nerve sparing technique (non-nerve sparing vs. full or partial nerve sparing) and SE. In multivariable models testing for CD ≥ 2 , adjustment variables consisted of Charlson comorbidity index (CCI) and SE. In multivariable models predicting UC recovery, covariates of interest were age at surgery, nerve sparing technique, CCI and SE. For all statistical analyses, R software environment for statistical computing and graphics (version 3.6.3) was used. All tests were two-sided with a level of significance set at $p < 0.05$.

Results

Descriptive characteristics of the study population

Table 1 resumes the characteristics of the entire population. Median age and BMI were 66 years (IQR: 61–71) and 26 kg/mq (IQR: 24–28), respectively. Fifty percent of the patients had a CCI of 2. Overall, 121 (37.8%) and 18 patients (5.6%) had a history of previous abdominal surgery and previous surgery for BPH (TURP for all cases) respectively. Median PSA at RS-RARP was 8.8 ng/ml (IQR 6.2–20). Overall, 99 patients (30.9%) had \geq clinical T3 disease and 204 patients (63.8%) ISUP grade ≥ 4 at prostate biopsy.

Intra-, peri- and post-operative outcomes

Median operative time and estimated blood loss were 200 min (IQR: 145–240) and 200 ml (IQR: 100–300), respectively (Table 1). A full nerve sparing was performed in 78 patients (24.4%). Nineteen patients (5.9%) harbored BML and the median prostate volume was 45 g (range 14–300). The median hospital stay and time to bladder catheter removal were 3 days (IQR 2–4) and 7 days (IQR 7–8), respectively. Supplementary Table 2a–b reported perioperative outcomes of patients with history of BPH surgery and with BML.

Table 1 Demographic, clinical and pathological characteristics of 320 high-risk prostate cancer patients treated with Retzius-sparing approach at a single European high-volume center

Pre-operative variables	Population, <i>n</i>	320
Age, years, median (IQR)		66 (61–71)
BMI, kg/mq, median (IQR)		26 (24–28)
Charlson comorbidity index, <i>n</i> (%)		
0–1		56 (17.5)
2		161 (50.3)
3		103 (32.2)
Previous abdominal surgery, <i>n</i> (%)		121 (37.8)
Previous surgery for BPH, <i>n</i> (%)		18 (5.6)
PSA at RS-RARP, ng/ml, median (IQR)		8.8 (6.2–20)
Clinical tumor stage, <i>n</i> (%)		
$\leq cT2a$		67 (20.9)
$cT2b$		95 (29.7)
$cT2c$		59 (18.5)
$\geq cT3$		99 (30.9)
ISUP grade group at prostate biopsy, <i>n</i> (%)		
1		39 (12.2)
2		37 (11.6)
3		40 (12.5)
4		158 (49.4)
5		46 (14.3)
Intra- and peri-operative variables		
Operative time, mins, median (IQR)		200 (145–240)
Bulky Median Lobe, <i>n</i> (%)		19 (5.9)
Bladder neck preservation, <i>n</i> (%)		
Full preservation		279 (87.2)
Partial preservation		36 (11.3)
Wide dissection		5 (1.5)
Nerve sparing technique, <i>n</i> (%)		
Full NS		78 (24.4)
Partial NS		44 (13.8)
Non-NS		198 (61.8)
Lymph node dissection, <i>n</i> (%)		
Extended*		308 (96.2)
Super-extended*		12 (3.8)
Estimated blood loss, ml, median (IQR)		200 (100–300)
Hospital stay, days, median (IQR)		3 (2–4)
Catheter removal, days, median (IQR; range)		7 (7–8; 3–34)
Pathological tumor stage, <i>n</i> (%)		
pT2		143 (44.7)
pT3a		101 (31.6)
$\geq pT3b$		76 (23.7)
Pathological ISUP grade group, <i>n</i> (%)		
1		21 (6.6)

Table 1 (continued)

Pre-operative variables	Population, <i>n</i>	320
2	62 (19.4)	
3	77 (24.1)	
4	94 (29.4)	
5	66 (20.5)	
Surgical margins, <i>n</i> (%)		
Negative margins	236 (73.8)	
Overall positive margins	84 (26.2)	
Focal	27 (8.4)	
Extended	57 (17.8)	
Total lymph nodes removed, median (IQR)	20 (16–25)	
Pathological nodal stage, <i>n</i> (%)		
pN0	268 (83.8)	
pN1	52 (16.2)	
Prostate volume, ml, median (range)	45 (14–300)	
Follow-up, months, median (IQR)	47 (24–70)	

BMI body mass index, *BPH* benign prostate hyperplasia, *PSA* prostate-specific antigen, *ISUP* international society of urological pathology, *RS-RARP* Retzius-sparing robot-assisted radical prostatectomy

*Pelvic lymph node dissection templates were defined as follows: extended=obturator, external, and internal iliac lymph nodes; super-extended=obturator, presacral, external, internal, and common lymph nodes

At multivariable linear regression analysis, PV ($p=0.03$) and previous BPH surgery (estimate 43.4, $p=0.02$) were independent predictors of operative time (Table 2). BML was the only independent predictor of time to bladder catheter removal (estimate 1.7, $p=0.001$), after accounting for multiple confounders (Table 2). Conversely, PV, BML and prior BPH surgery were not associated with neither blood loss nor length of stay (all $p \geq 0.4$; Table 2).

The final pathology revealed pathological \geq T3b disease in 76 patients (23.7%), pathological \geq ISUP grade 4–5 in 160 patients (50%) and PSM rate of 26.2% (Table 1). PSMs were focal in 27 patients (8.4%) and extended in 57 patients

(17.8%). Supplementary Table 2a–b reported the pathology of patients with history of BPH surgery and with BML.

At multivariable logistic regression model predicting PSMs, PV reached the independent predictor status (OR: 1.02; $p=0.009$, Table 3). Conversely, BML and prior BPH surgery did not predict higher PSMs (all $p \geq 0.1$). Overall, 52 90-day postoperative complications occurred in 44 patients (44/320 = 14%; Supplementary Table 1b). Eleven percent had at least one postoperative CD ≥ 2 . At multivariable logistic regression model predicting 90-day CD ≥ 2 , PV, BML and previous BPH surgery did not reach the independent predictor status (all $p \geq 0.2$; Table 3).

Overall, 53% of patients had immediate UC recovery at bladder catheter removal. The 1- and 2-yr UC recovery was 84 and 85%, respectively. UC recovery rates at bladder catheter removal, at 1 and at 2 yr from surgery for patients with BML and prior BPH surgery were displayed by Supplementary Table 2a–b. At multivariable Cox regression model, previous BPH surgery was significantly associated with urinary continence recovery (HR: 0.5; $p=0.03$; Table 4).

Discussion

Several commendable retrospective series [21–28] corroborated by four systematic reviews of the literature [3–5, 28] provided evidence that RS-RARP is technically reproducible and oncologically safe, with a special mention to its extraordinary functional outcomes (i.e., immediate UC recovery) [29]. Under this light, since 2020, the European Association of Urology (EAU) guidelines have included RS-RARP as treatment surgical option for PCa patients [1]. Nevertheless, none of the available evidence evaluated the potential detrimental effect of previous surgery for BPH, enlarged prostate and BML on perioperative, intermediate-term oncological and functional outcomes in the specific setting of high-risk PCa patients. Relying on a large series of high-risk PCa patients treated at a single high-volume center, we hypothesized that high-risk PCa patients with one of the aforementioned challenging features have worse perioperative

Table 2 Multivariable linear regression models predicting operative time, blood loss, length of stay and time to catheter removal in 320 prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy between 2011 and 2020 at a single high-volume center

	Operative time		Intraoperative Blood loss		Length of stay		Time to catheter removal	
	Estimate (95%CI)	<i>p</i> -value	Estimate (95%CI)	<i>p</i> -value	Estimate (95%CI)	<i>p</i> -value	Estimate (95%CI)	<i>p</i> -value
Prostate volume	–	0.03	–	0.8	–	0.7	–	0.9
Bulky median lobe	–18.5 (–54 to 17)	0.3	24 (–40 to 80)	0.5	–0.3 (–1.09 to 1.02)	0.9	1.7 (1–3)	0.001
Previous BPH surgery	43.4 (5.9–80)	0.02	–10 (–89 to 99)	0.8	–0.47 (–1.6 to 0.6)	0.4	–0.1 (–1.3 to 1.1)	0.5

All models were adjusted for BMI, ISUP grade group at biopsy (1–3 vs 4–5), clinical T stage (\leq T2 vs. T3), previous abdominal surgery and surgical experience

Table 3 Multivariable logistic regression models predicting positive surgical margins and 90-day Clavien–Dindo ≥ 2 in 320 prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy between 2011 and 2020 at a single high-volume center

	Positive surgical margins		Clavien–Dindo ≥ 2	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Prostate volume	1.02 (1.01–1.03)	0.009	0.98 (0.96–1.01)	0.2
Bulky median lobe	4.2 (0.9–10.6)	0.1	2.02 (0.7–5.5)	0.2
Previous BPH surgery	1.4 (0.5–4.8)	0.5	0.3 (0.02–1.9)	0.3
<i>ISUP grade group at biopsy</i>				
1–3	Ref	–	–	–
4–5	2.4 (1.4–4)	0.002		
<i>Clinical T stage</i>				
$\leq T2$	Ref	–	–	–
$\geq T3$	0.7 (0.4–1.3)	0.3		
<i>Nerve sparing</i>				
No nerve sparing	Ref	–	–	–
Full or partial nerve sparing	1.9 (1.1–3.5)	0.01		
Charlson Comorbidity Index	Ref	–	–	–
Surgical experience	1.01 (0.9–1.02)	0.6	0.97 (0.96–0.99)	0.04

Table 4 Multivariable Cox regression models predicting urinary continence recovery in 320 prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy between 2011 and 2020 at a single high-volume center

	HR (95% CI)	<i>p</i> -value
Prostate volume	0.9 (0.8–1.1)	0.3
Bulky median lobe	1.1 (0.6–1.9)	0.6
Previous BPH surgery	0.5 (0.3–0.8)	0.03
Age at surgery	0.8 (0.7–0.9)	0.02
<i>Nerve sparing</i>		
No nerve sparing	Ref	–
Full or partial nerve sparing	1.2 (1.01–1.5)	0.04
Charlson Comorbidity Index	0.7 (0.4–1.1)	0.2
Surgical experience	0.9 (0.9–1.2)	0.5

outcomes. Our findings partially confirmed our hypothesis, and several noteworthy observations are highlighted.

First, when the relationship between PV, BML, prior BPH surgery and perioperative outcomes was assessed, we observed that higher PV and previous BPH surgery significantly influenced operative time while blood loss and hospitalization did not suffer from any deviation from the usual ranges. As foreseeable, BML significantly increased the time to bladder catheter removal.

Second, we demonstrated that in terms of oncological safety, patients with enlarged prostate have significantly higher risk of PSMs (OR 1.02; $p=0.009$), even if the clinical significance might be scarce. Conversely, neither BML nor previous BPH surgery may affect the reliability of RS-RARP in terms of PSMs. Noteworthy, we failed to observe a relationship between SE and PSMs, suggesting that the learning process might be longer than expected [30] also in expert hands, as demonstrated in other settings [20]. Nevertheless,

the rate of PSMs observed in the current report, is in line with those reported for high-risk PCa patients treated with anterior approach [31, 32]. Our results are in contrast with previous findings that provided evidence that larger prostates were not significantly associated with higher risk of PSMs in PCa patients treated with RS-RARP [7]. However, the authors mainly relied on low- and intermediate-risk PCa patients [7]. Our findings should not rule out the need for surgical approach (i.e., RS-RARP) in high-risk PCa patients with enlarged prostate, given the excellent results in terms of functional outcomes (i.e., 1- and 2-yr UC recovery was 84 and 85%). The implementation of new imaging technologies for image-guided surgery on daily clinical practice that allow real-time understanding of surgical anatomy, might help to reduce the rate of PSMs especially in high-risk PCa patients with enlarged prostate treated with RS-RARP [33].

Third, when considering 90-d complications, we failed to observe an association with an increased risk of CD ≥ 2 for all three challenging scenarios (i.e., PV, BML, prior BPH surgery). Of note, SE is crucial to reduce the risk of CD ≥ 2 (OR 0.97, p value 0.04). The reliability of our findings is strengthened by the standardized methodology used to collect postoperative complications [14]. Although authors are still reluctant to use the mentioned methodology [17, 18], evidence suggested that its implementation is key to increase the complications rate detected relative to a collection system based on patient chart review and allowed to identify complications after discharge that would have been missed otherwise [16]. As consequence, our analysis represents the strongest study in terms of quality of complications report after RS-RARP.

Fourth, when functional outcomes were assessed, we observed that high-risk PCa patients who underwent previous BPH surgery have a consistently lower probability

of UC recovery, after accounting for multiple confounders ($p=0.03$). This might be explained by the presence of sticky tissue and less definable planes that made the surgery trickier. Conversely, enlarged prostate and BML did not impact on UC recovery. These findings are crucial to improve patient counseling, minimizing the regret and maximizing the satisfaction.

Unfortunately, our findings cannot be compared with other studies being the first to assess the relationship between previous surgery for BPH, enlarged prostate and BML and perioperative, intermediate-term oncological and functional outcomes in the specific setting of high-risk PCa patients.

Finally, our study is not devoid of limitations. This surgery is high-skill demanding and maybe not reproducible in centers without a consistent caseload and experience with the technique or for surgeons still in their learning process. The study is based on a retrospective analysis with all its inherent limitations, among whom the possibility of recall bias, considered the large span of time covered by our observations. Multi-centric studies relying on larger series are warranted, eventually comparing similar scenarios faced by different approaches.

Conclusion

In our RS-RARP series, high-risk PCa patients with enlarged prostate have higher risk of PSMs, while patients with prior BPH surgery have suboptimal UC recovery. These findings should help physicians for accurate preoperative counseling and to improve surgical planning (i.e., wider surgical resection) in case of high-risk PCa patients with enlarged prostates.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00345-022-04073-5>.

Author contributions Tappero: Project development, Data analysis, Manuscript writing. Dell'Oglio: Project development, Data analysis, Manuscript writing. Longoni: Data collection, Data analysis. Buratto: Data collection. Palagonia: Data collection, Data analysis. Scilipoti: Data collection. Vecchio: Data collection. Martiriggiano: Data collection. Secco: Project development, Data analysis. Olivero: Project development, Data analysis. Barbieri: Data collection. Napoli: Data collection. Strada: Data collection. Petralia: Critical revision of the manuscript, Important intellectual content. Di Trapani: Critical revision of the manuscript, Important intellectual content. Bocciardi: Project development, Critical revision of the manuscript, Important intellectual content, Supervision. Galfano: Project development, Manuscript writing, Supervision.

Funding The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Declarations

Conflict of interest The authors declare that there is no conflict of interests.

Ethics consent statement Due to the anonymously coded design of the employed database, study-specific Institutional Review Board ethics approval was not required.

Patient consent statement, permission to reproduce material from other sources and clinical trial registration Not applicable.

References

- Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2020.09.042>
- Galfano A, Ascione A, Grimaldi S et al (2010) A new anatomic approach for robot-assisted laparoscopic prostatectomy: a feasibility study for completely intrafascial surgery. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2010.06.008>
- Phukan C, Mclean A, Nambiar A et al (2020) Retzius sparing robotic assisted radical prostatectomy vs conventional robotic assisted radical prostatectomy: a systematic review and meta-analysis. *World J Urol*. <https://doi.org/10.1007/s00345-019-02798-4>
- Checucci E, Vecchia A, Fiori C et al (2020) Retzius-sparing robot-assisted radical prostatectomy vs the standard approach: a systematic review and analysis of comparative outcomes. *BJU Int*. <https://doi.org/10.1111/bju.14887>
- Rosenberg JE, Jung JH, Edgerton Z et al (2020) Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. *Cochrane Database Syst Rev*. <https://doi.org/10.1002/14651858.CD013641.pub2>
- Dell'Oglio P, Tappero S, Longoni M et al (2022) Retzius-sparing robot-assisted radical prostatectomy in high-risk prostate cancer patients: results from a large single-institution series. *Eur Urol Open Sci* 38:69–78. <https://doi.org/10.1016/j.euros.2022.02.007>
- Galfano A, Panarello D, Secco S, et al (2018) Does prostate volume have an impact on the functional and oncological results of Retzius-sparing robot-assisted radical prostatectomy? *Minerva Urologica e Nefrologica* <https://doi.org/10.23736/S0393-2249.18.03069-2>
- Qian J, Fu Y, Wu X, et al (2021) Impact of protruded median lobe on perioperative, urinary continence and oncological outcomes of Retzius-sparing robot-assisted radical prostatectomy. *Transl Androl Urol* 10:538–547. <https://doi.org/10.21037/tau-20-1229>
- Kim LHC, Santok GD, Raheem AA et al (2018) Retzius-sparing robot-assisted radical prostatectomy is safe for patients with prior transurethral prostate surgery. *Int Braz J Urol* 44:842–843. <https://doi.org/10.1590/s1677-5538.ibju.2017.0316>
- Stonier T, Simson N, Davis J, Challacombe B (2019) Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) vs standard RARP: it's time for critical appraisal. *BJU Int* 123:5–7. <https://doi.org/10.1111/bju.14468>
- D'Amico AV (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA*. <https://doi.org/10.1001/jama.280.11.969>
- Jeong CW, Lee S, Oh JJ et al (2014) Quantification of median lobe protrusion and its impact on the base surgical margin status

- during robot-assisted laparoscopic prostatectomy. *World J Urol* 32:419–423. <https://doi.org/10.1007/S00345-013-1118-Z>
13. Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications. *Ann Surg*. <https://doi.org/10.1097/SLA.0b013e3181b13ca2>
 14. Mitropoulos D, Artibani W, Graefen M et al (2012) Reporting and grading of complications after urologic surgical procedures: an ad hoc eau guidelines panel assessment and recommendations. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2011.10.033>
 15. Mazzone E, D'Hondt F, Beato S et al (2021) Robot-assisted radical cystectomy with intracorporeal urinary diversion decreases postoperative complications only in highly comorbid patients: findings that rely on a standardized methodology recommended by the European Association of Urology Guidelines. *World J Urol*. <https://doi.org/10.1007/s00345-020-03237-5>
 16. Gandaglia G, Bravi CA, Dell'Oglio P et al (2018) The impact of implementation of the european association of urology guidelines panel recommendations on reporting and grading complications on perioperative outcomes after robot-assisted radical prostatectomy. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2018.02.025>
 17. Dell'Oglio P, Andras I, Ortega D et al (2021) Impact of the implementation of the EAU guidelines recommendation on reporting and grading of complications in patients undergoing robot-assisted radical cystectomy: a systematic review. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2021.04.030>
 18. Cacciamani GE, Maas M, Nassiri N et al (2021) Impact of pelvic lymph node dissection and its extent on perioperative morbidity in patients undergoing radical prostatectomy for prostate cancer: a comprehensive systematic review and meta-analysis. *Eur Urol Oncol*. <https://doi.org/10.1016/j.euo.2021.02.001>
 19. Vickers AJ, Savage CJ, Hruza M et al (2009) The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. *Lancet Oncol* 10:475–480. [https://doi.org/10.1016/S1470-2045\(09\)70079-8](https://doi.org/10.1016/S1470-2045(09)70079-8)
 20. Dell'Oglio P, Mazzone E, Lambert E et al (2021) The effect of surgical experience on perioperative and oncological outcomes after robot-assisted radical cystectomy with intracorporeal urinary diversion: evidence from a referral centre with extensive experience in robotic surgery. *Eur Urol Focus* 7:352–358. <https://doi.org/10.1016/j.euf.2020.01.016>
 21. Sayyid RK, Simpson WG, Lu C et al (2017) Retzius-sparing robotic-assisted laparoscopic radical prostatectomy: a safe surgical technique with superior continence outcomes. *J Endourol*. <https://doi.org/10.1089/end.2017.0490>
 22. Dalela D, Jeong W, Prasad M-A et al (2017) A pragmatic randomized controlled trial examining the impact of the Retzius-sparing approach on early urinary continence recovery after robot-assisted radical prostatectomy. *Eur Urol*. <https://doi.org/10.1016/j.eururo.2017.04.029>
 23. Li-Wen Chang, Sheng-Chun Hung, Ju-Chuan Hu, Kun-Yuan Chiu (2018) Retzius-sparing robotic-assisted radical prostatectomy associated with less bladder neck descent and better early continence outcome. *Anticancer Res* <https://doi.org/10.21873/anticancer.12228>
 24. Asimakopoulos AD, Topazio L, de Angelis M et al (2019) Retzius-sparing versus standard robot-assisted radical prostatectomy: a prospective randomized comparison on immediate continence rates. *Surg Endosc*. <https://doi.org/10.1007/s00464-018-6499-z>
 25. Lim SK, Kim KH, Shin T-Y et al (2014) Retzius-sparing robot-assisted laparoscopic radical prostatectomy: combining the best of retroperic and perineal approaches. *BJU Int*. <https://doi.org/10.1111/bju.12705>
 26. Egan J, Marhamati S, Carvalho FLF et al (2021) Retzius-sparing robot-assisted radical prostatectomy leads to durable improvement in urinary function and quality of life versus standard robot-assisted radical prostatectomy without compromise on oncologic efficacy: single-surgeon series and step-by-step guide. *Eur Urol* 79:839–857. <https://doi.org/10.1016/j.eururo.2020.05.010>
 27. Menon M, Dalela D, Jamil M et al (2018) Functional recovery, oncologic outcomes and postoperative complications after robot-assisted radical prostatectomy: an evidence-based analysis comparing the retzius sparing and standard approaches. *J Urol* 199:1210–1217. <https://doi.org/10.1016/j.juro.2017.11.115>
 28. Umari P, Eden C, Cahill D et al (2021) Retzius-sparing versus standard robot-assisted radical prostatectomy: a comparative prospective study of nearly 500 patients. *J Urol*. <https://doi.org/10.1097/JU.0000000000001435>
 29. Tai T-E, Wu C-C, Kang Y-N, Wu J-C (2020) Effects of Retzius sparing on robot-assisted laparoscopic prostatectomy: a systematic review with meta-analysis. *Surg Endosc*. <https://doi.org/10.1007/s00464-019-07190-2>
 30. Galfano A, Secco S, Dell'Oglio P et al (2021) Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents. *BJU Int* 127:412–417. <https://doi.org/10.1111/bju.15196>
 31. Abdollah F, Dalela D, Sood A et al (2016) Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. *World J Urol*. <https://doi.org/10.1007/s00345-016-1781-y>
 32. Kumar A, Samavedi S, Bates AS et al (2017) Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy. *J Robot Surg*. <https://doi.org/10.1007/s11701-016-0627-3>
 33. Porpiglia F, Checucci E, Amparore D et al (2019) Augmented-reality robot-assisted radical prostatectomy using hyper-accuracy three-dimensional reconstruction (HA3D™) technology: a radiological and pathological study. *BJU Int* 123:834–845. <https://doi.org/10.1111/bju.14549>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.